FDA, CDC, AND FSIS AND THE SHEEP INDUSTRY – UPDATES

Dr. Rosie Busch

Sheep and Goat Veterinary Medicine Extension Specialist

UC Davis School of Veterinary Medicine

January 2025

Alphabet Soup…


APHIS


USDA
ars
Agricultural Research Service


USDA
Food
Safety and
Inspection
Service

“One Health” According to FDA & CDC

National Antimicrobial Resistance Monitoring System (NARMS)

Table 2. Number of positive isolates per number of samples screened for each organism and slaughter class, 2020-2022.

Organism	Goat			Sheep			Lamb		
	No. of samples screened[1]	No. of positives	% positive	No. of samples screened[1]	No. of positives	% positive	No. of samples screened[1]	No. of positives	% positive
Salmonella	349	43	12%	319	107	34%	357	75	21%
Campylobacter	175	46	26%	159	58	36%	186	70	38%
Generic *E. coli*	103	84	82%	87	72	83%	105	90	86%
Enterococcus	98	79	81%	84	69	82%	100	78	78%

[1] Not all samples collected were screened for all organisms; hence, the number of samples screened vary. For generic *E. coli* and *Enterococcus*, lower number of samples were screened due to their high rate of recovery (percent positive) while recovery of *Salmonella* and *Campylobacter* was relatively lower.

Dessai, Uday, et al. "Antimicrobial Resistance in Bacteria Isolated from US Goat, Sheep, and Lamb Cecal Content Samples: A FSIS NARMS Study." (2024).

Figure 2. Distribution of aggregated bacterial AMR categories for goat, sheep, and lamb combined, 2020-2022.



Dessai, Uday, et al. "Antimicrobial Resistance in Bacteria Isolated from US Goat, Sheep, and Lamb Cecal Content Samples: A FSIS NARMS Study." (2024).

NIAA @ CDC


CDC
GIANT microbes®
Diarrhea
www.giantmicrobes.com
1,000,000x+ actual size
Image of C. jejuni

FDA Animal and Veterinary Innovation Agenda

- New Director of CVM: Tracey Farfa, JD, Mdiv
- MUMS Director: Dorothy Bailey

Unfortunately, with this trend toward less investment in researching and developing antiparasitic drugs, especially ones for small ruminants,[12] the likelihood that new antiparasitic drugs for sheep and goats will be available in the U.S. in the near future is low. Despite this challenge, the ARMS group thinks that **today** is the best time for drug companies to pursue approval of new antiparasitic drugs for sheep and goats. Companies should start the drug development process **now** to ensure that new antiparasitic drugs will be available in the next decade. FDA is interested in working with companies on innovative ways to meet the drug approval requirements. For example, companies may be able to use published literature and foreign data to satisfy some of these requirements.

USDA Center for Veterinary Biologics